GSK’s experimental HIV drug trial produces positive results

GSK’s experimental HIV drug trial produces positive results

U.K.-based GlaxoSmithKline PLC’s ViiV Healthcare on Tuesday announced positive results for its phase-three trial of its experimental HIV drug in a dual-drug regimen.

The company announced that the combination of its HIV pill dolutegravir and Johnson & Johnson’s (J&J’s) rilpivirine drug successfully suppressed the HIV virus as capably as the existing three- or four-drug regimen can.

The positive results of the year-long trial, involving nearly 500 patients, supported Glaxo’s bold bet that it can shift the HIV treatment orthodoxy away from three-drug combinations to two-drug regimen.

The results of the trial also raised the possibility of a challenge to incumbent companies like Gilead.

UBS analyst Michael Leuchten said, “The key debate remains whether Gilead will gain the upper hand again or whether a disruptive two-drug regimen becomes standard of care, favoring GSK.”

Reducing the number of drugs will lower antiretroviral medicine’s side effects, such as nausea, diarrhea, bone-thinning and kidney problems. In addition, it will lighten the patient’s financial burden.

Dominique Limet, the chief of ViiV Healthcare, said the two-drug regimen would be submitted to regulators sometime next year. However, both medicines used in the two-drug regimen are already sold as components in combinations of three or more drugs.


Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More